Get the Stockscreener App
0.67
0.89%
-0.006
Can-Fite Biopharma Ltd ADR stock is traded at $0.67, with a volume of 107.55K.
It is down -0.89% in the last 24 hours and down -36.19% over the past month.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
See More
Previous Close:
$0.676
Open:
$0.6768
24h Volume:
107.55K
Relative Volume:
0.64
Market Cap:
$1.03M
Revenue:
$743.00K
Net Income/Loss:
$-7.63M
P/E Ratio:
-0.2233
EPS:
-3
Net Cash Flow:
-
1W Performance:
-33.66%
1M Performance:
-36.19%
6M Performance:
-54.73%
1Y Performance:
-79.00%
1-Day Range:
$0.66
$0.68
1-Week Range:
$0.6577
$1.01
52-Week Range:
$0.6577
$3.24
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADR
Sector
Industry
Phone
972 3 924 1114
Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.67 | 9.19M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.62 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.42 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
388.26 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.48 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
300.26 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-17 | Initiated | Maxim Group | Buy |
| Oct-19-16 | Resumed | ROTH Capital | Buy |
| Aug-29-16 | Resumed | Rodman & Renshaw | Buy |
| Nov-30-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-31-15 | Reiterated | H.C. Wainwright | Buy |
| Mar-30-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-29-14 | Reiterated | ROTH Capital | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
View All
Can-Fite Biopharma Ltd ADR Stock (CANF) Latest News
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial By Investing.com - Investing.com South Africa
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs By Investing.com - Investing.com India
Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Reckitt Benckiser Group PLC (OTC: RBGLY) - Business Wire
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands - Business Wire
Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
NOVONIX to Commence Trading on Nasdaq through Level II ADR Program - Business Wire
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
Global Metal Casting Market 2020-2024 | Evolving Opportunities with Acast and Alcast Co. | Technavio - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
Can-Fite Biopharma Ltd ADR Stock (CANF) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):